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Focused CRISPR‑Cas9 genetic
screening reveals USO1
as a vulnerability in B‑cell acute
lymphoblastic leukemia
Amit Kumar Jaiswal1, Hellen Truong1, Tiffany M. Tran1,2, Tasha L. Lin3, David Casero4,
Michael O. Alberti5 & Dinesh S. Rao1,6,7*
Post-transcriptional gene regulation, including that by RNA binding proteins (RBPs), has recently been
described as an important mechanism in cancer. We had previously identified a set of RBPs that were
highly dysregulated in B-cell acute lymphoblastic leukemia (B-ALL) with MLL translocations, which
carry a poor prognosis. Here, we sought to functionally characterize these dysregulated RBP genes
by performing a focused CRISPR dropout screen in B-ALL cell lines, finding dependencies on several
genes including EIF3E, EPRS and USO1. Validating our findings, CRISPR/Cas9-mediated disruption
of USO1 in MLL-translocated B-ALL cells reduced cell growth, promoted cell death, and altered the
cell cycle. Transcriptomic analysis of USO1-deficient cells revealed alterations in pathways related
to mTOR signaling, RNA metabolism, and targets of MYC. In addition, USO1-regulated genes from
these experimental samples were significantly and concordantly correlated with USO1 expression in
primary samples collected from B-ALL patients. Lastly, we found that loss of Uso1 inhibited colony
formation of MLL-transformed in primary bone marrow cells from Cas9-EGFP mice. Together, our
findings demonstrate an approach to performing focused sub-genomic CRISPR screens and highlight
a putative RBP vulnerability in MLL-translocated B-ALL, thus identifying potential therapeutic targets
in this disease.
B-ALL is the most common type of leukemia in the pediatric population, and is characterized by a number of
recurrent chromosomal rearrangements1–4. Among these, the t (4;11) MLL-AF4 (KMT2A-AFF1) translocation
gives rise to a highly aggressive form of B-ALL5,6. Patients with MLL-rearranged B-ALL have a dismal prognosis,
with 5-year event-free survival rates hovering at 33.6% for i nfants7 and 50% for older children and a dults8. Most
of these patients are resistant to conventional treatment with chemotherapy and steroids9, with bone marrow
transplantation being the only curative therapeutic a lternative10. Although recent developments such as CAR-T
therapy11 and anti-CD19 based therapy such as B
 linatumomab12 have raised hope for such p
 atients13, antigen
escape and lineage infidelity in MLL-translocated leukemia have proved problematic14. Therefore, there is an
urgent need to better characterize potential therapeutic targets with high specificity.
The MLL-AF4 translocation engenders a unique transcriptional profile, as the fusion protein juxtaposes
a histone methyltransferase (MLL, also known as KMT2A) with a protein that is involved in transcriptional
regulation (AF4, or AFF1). Recently our lab carried out a study examining the expression of RBPs in B-ALL15,
including both known and predicted R
 BPs16. In our analysis, we identified 36 RBPs that are highly upregulated
in MLL-AF4 translocated B-ALL15. To study the importance of these genes in B-ALL, we implemented the powerful gene editing technique, CRISRP/Cas9, to perform a rapid and medium-throughput assessment of gene
function. Genome wide CRISPR/Cas9 screens on AML cell lines have identified multiple gene targets critical for
cell proliferation and s urvival17, but similar studies have not been performed in MLL-AF4 translocated B-ALL.
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In the present study, we performed a sub-genomic CRISPR/Cas9 dropout screen using 36 highly upregulated
RBPs in primary human B-ALL and identified several novel vulnerabilities that included three putative RBPs. Of
these, USO1, a putative RBP and a known regulator of vesicular transport, was identified as a MLL-AF4 target
gene. CRISPR/Cas9-mediated disruption of USO1 significantly altered cell growth and the cell cycle in B-ALL
cell lines; as well as inhibited the colony forming potential of MLL-transformed primary murine bone marrow
cells. USO1 depletion regulated the expression of genes related to mTOR signaling, metabolism of RNA, and
MYC targets. Together, our studies provide a comprehensive rubric to functionally evaluate putative targets identified from expression profiling, and the identification of a novel potential target in MLL-rearranged leukemia.

Results

CRISPR/Cas9 screen identifies potential vulnerabilities in MLL‑AF4 leukemic cell growth. Previously, we identified 36 putative RBPs that were significantly dysregulated in primary human MLL-rearranged
B-ALL15. To directly query the functional relevance of RBP dysregulation in MLL-rearranged B-ALL, we performed a sub-genomic CRISPR screen (Fig. 1A). The library consisted of sgRNAs targeting 36 RBP genes, 12
“positive control” genes, representing known vulnerabilities in MLL-translocated leukemia17, and 28 non-targeting (NT) sgRNAs. The screen was designed using a two-vector lentiviral system. First, B-ALL cells with
and without MLL-AF4 translocation (SEM and NALM6, respectively) were stably transduced with a Cas9-P2AEGFP transgene, followed by FACS sorting of the transduced cells based on GFP positivity. Next, Cas9-GFP+
SEM and NALM6 cells were transduced at a MOI of < 0.3 with the pooled sgRNA lentiviral library, comprised of
268 unique sgRNAs. Cells were subsequently FACS sorted 48 h following transduction for GFP and tRFP double
positivity (Fig. 1B). 2 × 106 cells were sorted, of which 106 cells were used to isolate genomic DNA for the reference (REF) libraries and the remainder were cultured to maintain 3700 × coverage until collection of genomic
DNA for the depletion (DEP) libraries following 28 days in culture. Experimental replicates of REF and DEP
libraries showed a high degree of concordance in abundance of both individual sgRNAs and for total sgRNAs
per gene (Supplementary Fig. 1D & 1E). In addition, the SEM and NALM6 REF libraries showed overall similar
rates of individual gRNA incorporation, as measured by the abundance of each gRNA in each of the cell lines
and biological replicates (Supplementary Fig. 1F). As expected, a majority of “positive control” genes, including
BCL2, COA5, CDK6, and MYC, were significantly downregulated in the DEP libraries in both NALM6 and SEM
cells. This is not surprising as many of these are known oncogenic genes, particularly in B-ALL. Non-targeting or
“negative control” sgRNAs were consistently unchanged between the REF and DEP libraries (Fig. 1C, D). Comparing the results across cell lines, we found that sgRNAs targeting three genes, USO1, EIF3E and EPRS were
significantly depleted in SEM cells (p < 0.001), when compared to NALM6 cells (Fig. 1E). Interestingly, sgRNA
dropout in general was more readily observed in SEM cells than in NALM6 cells, potentially due to the fact that
these genes were selected based on high expression in patient B-ALL samples with MLL-AF4 translocation. Of
these three genes, USO1 had previously been detected in a genome-wide CRISPR screen as a vulnerability in
MV-4–11 cells, which also harbor the MLL-AF4 fusion gene17.
USO1 is directly regulated by MLL‑AF4.

USO1, EPRS and EIF3E expression was assessed in, SEM,
RS4;11 (another MLL-AF4 translocated cell line), and NALM6 (Supplementary Fig. 2A & 2B). To query their
regulation by the MLL-AF4 fusion protein, we analyzed their expression following inhibition with I-BET15118, a
BRD4 BET domain inhibitor, MI-503 menin-MLL1 inhibitor19 and EPZ5676, a DOT1L inhibitor20, all known to
inhibit MLL-dependent gene expression regulation. With increasing doses of I-BET151, MI-503 and EPZ5676
there was a decrease in the USO1 mRNA expression level in SEM (Fig. 2A), and RS4;11 cells (Fig. 2B), but
not in NALM6 cells (Fig. 2C as well as Supplementary Fig. 2C, 2D & 2E), suggesting that USO1 expression is
MLL-AF4 dependent. A consistent reduction in EIF3E and EPRS was not observed in the MLL translocated cell
lines. We further queried the MLL dependence of USO1 by over-expressing the MLL-Af4 t ransgene21 in murine
bone marrow cells. Western Blot and RT-qPCR analysis showed upregulation of MLL1 and USO1 in MLL-Af4
transduced cells compared to control cells (Fig. 2D and Supplementary Fig. 2F). Using publicly available d
 ata21,
we found that the USO1 and EIF3E genes demonstrated multiple MLL-AF4 binding sites within the 5’UTR, the
first exon, and the first intron (Fig. 2E and Supplementary Fig. 2G). In contrast, the EPRS gene did not show
strong MLL-AF4 binding sites (Supplementary Fig. 2H). EIF3e and EPRS were previously reported to be “common essential genes”, per the depmap portal22, whereas USO1 was not such a gene, suggesting its potential utility
as a novel clinical target. To confirm our findings of USO1 dependence on MLL-AF4, we designed chromatin
immunoprecipitation (ChIP) experiments, designing primers for the regulatory regions of USO1 including the
5’ UTR within the first exon. We found significant enrichment of the USO1 regulatory regions in both the MLL1
and AF4 pulldowns (Fig. 2F). Treatment of the cells with I-BET151 inhibited the association of both MLL1 and
AF4 with the promoter region of USO1 (Fig. 2G). Together, these findings indicate that USO1 is a direct target
of the MLL-AF4 transcriptional program.

USO1 depletion alters B‑ALL cell proliferation, survival and cell cycle. USO1 expression is

upregulated in several types of cancer including B-ALL with MLL-AF4 translocations23–25. To characterize the
functional role of USO1 in B-ALL suggested by our CRISPR screen, we utilized the previously mentioned twovector lentivirus system to transduce SEM cells with three different lentiviral constructs containing sgRNAs
that target different regions of the USO1 gene (Fig. 3A, B). We found that two sgRNAs (sg2 and sg3) caused a
significant downregulation of USO1 protein and mRNA expression by approximately 80% in SEM cells (Fig. 3C,
D). Cas9-mediated frameshift mutation in USO1 was confirmed using TIDE a ssay26 (Supplementary Fig. 3A).
The lack of complete ablation was a reproducible finding in all cell lines we tested, as multiple single-cell cloning experiments failed to produce cells with complete knockout and multiple bulk cultures experiments showed
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Figure 1.  Sub-genomic CRISPR screen identifies functionally important genes in MLL-AF4-translocated
B-ALL. (A) Schematic of sub-genomic CRISPR screen. (B) FACS contour plots reflecting sorting strategy based
on high expression of Cas9 (GFP) and pooled guide RNA library (tRFP) in B-ALL cell lines. (C, D) Variancestabilized normalized abundance for individual sgRNAs in Reference (Ref; x-axis) and Depletion (Dep; y-axis)
libraries in SEM (C) and NALM6 (D) cell lines. Dots are colored by sgRNA class (dark yellow: positive controls;
black: non-targeting negative controls; teal: targeting sgRNAs). Dots highlighted with a red border were
classified as differentially abundant (Log2 fold change [Log2FC] > 1, Wald adjusted p value < 0.001). Genes with
three or more differential sgRNAs are highlighted in the inset and colored by class. (E) Differential expression of
sgRNAs aggregated by gene ( Log2FC gene total), in NALM6 (x-axis) vs SEM (y-axis) cell lines. Dots in the upper
left represent genes with a higher fold-change in SEM cells, while those on the lower right represent genes with
a higher fold-change in NALM6 cells. Dots are colored by sgRNA class and sized according to the number of
individual sgRNAs that showed significant differential representation in the Dep libraries.
retained partial expression of < 25%. Nonetheless, we observed that bulk USO1-depleted SEM cells from sg2
and sg3 showed reduced proliferation by MTS assay (Fig. 3E). Since sg3 showed near-total ablation of USO1
protein expression, we later used sg3 to target USO1 in RS4;11 cells (Supplementary Fig. 3B & 3C), finding
downregulation, but not complete depletion, of USO1 protein. Propidium Iodide (PI) based cell cycle analysis
on USO1-depleted cells showed an increased percentage of cells in the G0/G1 stage, suggesting cell cycle arrest,
and more cells in Sub-G0/G1, suggesting increased apoptosis (Fig. 3F, G). Increased cell death was also observed
in the USO1-depleted cells by Annexin V staining (Fig. 3H, I). Interestingly, USO1-depleted cells treated with
I-BET151 also showed increased cell cycle arrest and apoptosis (Supplementary Fig. 3D–3G), suggesting an
additive effect with this inhibitor of BRD4. To confirm our findings in an orthogonal system, we introduced siRNAs targeting USO1 using nucleofection. In these short-term assays, we found that there was partial reduction of
USO1 mRNA, as expected with siRNA-mediated knockdown (Supplementary Fig. 4A) and increased Annexin
V staining (Supplementary Fig. 4B, C). There were also increased cells in Sub-G0/G1 and a modest reduction in
cell proliferation as measured by the MTS assay (Supplementary Fig. 4E, F). Together, these observations confirm the importance of USO1 in regulation of cell cycle and survival of B-ALL cells.
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Figure 2.  Dependence of RBP gene expression on MLL-AF4 translocation. (A–C) Effect of I-BET 151 and MI-503 treatment on
mRNA expression levels of USO1,EPRS and EIF3E, measured by RT-qPCR, in SEM (A), RS4;11 (B), and NALM6 (C). The cells were
treated with increasing concentrations of I-BET151 (DMSO only, 0.5, 1 and 2 μM) or with increasing concentrations of the menin
inhibitor, MI-503 (DMSO only, 0.12, 0.25, and 0.5 μM). RT-qPCR was performed with an optimized set of primers, normalized to
18S, and then represented as fold-change from vehicle-treated control. D. Western blot analysis of murine bone marrow cells with
and without transduction with MLL-Af4 (WT versus MLL-Af4), for MLL1 (top), USO1 (middle) and β-actin (lower). (E) UCSC
genome browser shot of the USO1 locus showing the MLL-AF4 ChIP site(s), as identified from the ChIP-Seq data from Lin et al.21,
in a gene expression regulatory region; Courtesy: UCSC Genome Browser. Shown are the H3K27Ac track in hematopoietic K562 cells
(Blue), and MLL-AF4 binding sites represented as a grayscale score, with black indicating the highest score/highest number of reads
from the dataset. (F) Chromatin immunoprecipitation with indicated antibodies (MLL1, AF4, and RNA Pol II), followed by qPCR
(ChIP-qPCR) analysis for quantitation of bound USO1 promoter/regulatory region to MLL1 and AF4 pulldown samples. Shown is the
fold-enrichment for qPCR of the USO1 regulatory site over background (t test; *P < 0.05) (G) SEM cells treated with 1 µM of I-BET151
for 48 h. and subjected to ChIP qPCR with MLL1 and AF4 antibodies as in (F) (t test; *P < 0.05).
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Figure 3.  Depletion of USO1 leads to decreased cell growth, cell cycle arrest and increased apoptosis. (A) Schematic representation
of the pLKO5.sgRNA.EFS.tRFP lentiviral vector. Abbreviations, hU6, human U6 promoter; sgRNA, short guide RNA; sg scaf, sgRNA
scaffold; tRFP, turbo red fluorescent protein. (B) Sample FACS plots of SEM cells transduced sequentially with Cas9 vector and sgRNA
containing vector. Left, non-transduced SEM cells; middle, transduced with pLentiCas9-GFP; right, cells transduced with both
pLenti-Cas9-GFP and pLKO5 vector containing USO1-targeting sgRNA. (C) Western blot for USO1 in SEM cells following CRISPR/
Cas9-mediated disruption of the USO1 gene using three different sgRNAs (sg1-3) and NT, non-targeting sgRNAs. (D) RT-qPCR
measurement of USO1 in control (NT) and USO1 (sg2 & sg3) SEM cells (t test; **P < 0.01; ****P < 0.0001) (E) MTS assay to study the
cell growth of USO1-depleted cells (sg2 & sg3), measured as Absorbance at 490 nM (t test; **P < 0.01; ***P < 0.001). (F, G) Cell cycle
analysis using propidium iodide (PI) staining of control cells and USO1-depleted cells (F) and quantitation of cells from cell cycle
analysis (Two-way Annova with Bonferroni correction; *P < 0.05; ****P < 0.0001). (H, I) FACS plots of Annexin V positivity in control
versus USO1-depleted cells (H), Quantitation of cells with Annexin V positivity (t test; **P < 0.01) (I).
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USO1 impacts pathways related to cellular proliferation and RNA homeostasis. To evaluate
the effect of USO1 depletion on the overall gene expression pattern in B-ALL cells, we performed RNA-Seq on
SEM cells that were depleted of USO1 by CRISPR/Cas9 (three biological replicates per condition). Following
differential expression analysis of USO1-depleted and control cells, we utilized the Metascape algorithm and
Gene set enrichment analysis (GSEA) to assess pathway e nrichment27,28. We found that significantly downregulated pathways included MTOR, ERB2, and Hallmark Hypoxia, while upregulated terms included Metabolism
of RNA and Hallmark MYC targets (Fig. 4A and Supplementary Fig. 5A). Analysis of Gene Ontology -Molecular
Function gene sets revealed positive enrichment of several gene sets related to RNA homeostasis in the USO1depleted cells (Supplementary Fig. 5B). Selected examples of up- and down regulated genes (log2FC > 1.5 and
Padj. value < 0.01), from the enriched pathway identified by GSEA are highlighted in the Volcano plot for RNAseq data (Fig. 4B). RT-qPCR was used to confirm these same significantly upregulated (TFRC, MRPS12, and
PSMD1) (Fig. 4C) and downregulated genes (BAPIP2, ABCA1 and BTAF1) (Fig. 4D) in USO1-depleted SEM
cells. This led us to hypothesize that there were alterations in expression and activation of MTOR in USO1depleted cells using western blotting. We observed there was a mild downregulation of p-MTOR (Ser2481) in
the USO1-depleted cells (Fig. 4E). Hence, it appears that USO1 regulates several pathways that are known to play
a role in cell survival and cell death29.
To assess whether the gene expression changes caused by USO1-depletion had any clinical relevance, we
turned to the Target Phase II Acute lymphoblastic leukemia dataset, accessed via the cBioPortal interface30,31.
We calculated correlation coefficients between USO1 and 24,278 genes detected by RNA-seq in 203 samples
from 154 patients. Using a cut-off q value of 0.001, we then overlapped genes up- or down-regulated in USO1depleted with genes that had either a positive or negative correlation co-efficient. We found a highly significant
overlap between genes that were positively correlated with USO1 across the B-ALL samples and downregulated in
USO1-depleted cells (Hypergeometric test; p < 0.0001), but not in genes that were upregulated in USO1-depleted
cells (non-significant p value) (Fig. 4F, Supplementary 5C & 5D). This suggests that USO1 regulates gene expression in patient samples of B-ALL. As concrete examples, differentially expressed genes confirmed by RT-qPCR
(Fig. 4C, D) showed a direct correlation with USO1 expression in the ALL dataset from cBioPortal (Supplementary Fig. 6A–6D). These findings strongly suggest that USO1 plays a role in gene regulation in human B-ALL.
USO1 inhibits the MLL‑AF4‑driven leukemogenesis in primary murine bone marrow
cells. Having demonstrated that USO1 is required for the survival and growth of MLL-AF4+ cells in culture,

we wanted to determine if USO1 was required in an experimentally induced primary cell model of MLL-AF4driven leukemia. Briefly, L
 in- cells from the bone marrow of Cas9-EGFP mice32 were transduced with MLL-Af4
retrovirus33 (Fig. 5A) and selected with G418. We confirmed expression of the MLL-Af4 transgene, finding
overexpression by RT-qPCR and western blot analysis (Fig. 5B). As expected, we observed rapid proliferation
and expansion of the Lin- Cas9MLL-Af4 cells. In order to deplete Uso1 from these cells, we designed and cloned
three Uso1 murine specific sgRNAs (msg2 and msg3) into our internally designed MSCV.EFs.mCherry retroviral vector. To determine their effectiveness, we sorted G
 FP+ mCherry+ 70Z/3 cells transduced with the MSCV
retroviruses, briefly expanded them in culture, and then queried USO1 expression. Western blot and RT-qPCR
demonstrated that msg2 and msg3 both resulted in significant reduction of USO1 protein and mRNA expression (Fig. 5C, D). Uso1-depleted 7OZ/3 cells also had reduced cell growth by MTS assay which correlated with
the different levels of USO1 depletion for msg2 and msg3 (Fig. 5E). From these data, the msg3 retrovirus was
selected for transduction of L
 in- Cas9MLL-Af4 cells. After sorting G
 FP+ mCherry+ transduced Lin- Cas9MLL-Af4
cells (Fig. 5F), USO1-depletion was confirmed by western blot, in which protein expression was reduced to
26% (Fig. 5G), and the cells were subsequently used in a colony formation assay. Functionally, USO1-depletion
resulted in significantly fewer colonies in Lin-Cas9MLL-Af4 cells compared to NT control cells at 12 days. This
change was maintained at several different starting numbers of L
 in-Cas9MLL-Af4 cells (Fig. 5H). Hence, the function of USO1 is preserved in not only in human B-ALL cell lines but also in primary murine MLL-Af4 transformed cells.

Discussion

The molecular mechanism of MLL-AF4 driven leukemogenesis remains incompletely understood, and this
subtype of B-ALL is highly aggressive5,7. Although there are several fusion partners for MLL in acute leukemia,
downstream transcriptional dysregulation is a common f eature15,34,35. In this study, we sought to understand
whether overexpression of putative RBPs, which we identified previously, contributes to the pathogenesis of
MLL-AF4+ B-ALL15. We performed a focused sub-genomic CRISPR/Cas9 dropout screen to specifically address
whether these putative RBPs had a functional role in leukemia cell growth. Indeed, we identified three genes
(EIF3E, EPRS, and USO1 ) that appeared to be required in the MLL-AF4+ cell line, SEM. These genes showed
slightly higher rates of dropout in SEM cells than in NALM6 cells. Of these, USO1 expression showed a dependence on MLL-AF4, whereas EIF3E and EPRS did not show the same dependence and were previously reported
to be “common essential genes”, per the depmap p
 ortal22. Follow-up studies confirmed a role for USO1, both in
cell lines and in a model of MLL-AF4 driven leukemia in primary murine bone marrow cells. RNA sequencing
revealed that USO1 regulates numerous pathways, including mTOR, MYC targets, as well as elements of RNA
homeostasis.
One of the challenges of genomic-scale CRISPR screens is that genes with a small average effect size on the
phenotype of interest can be quite difficult to identify and can frequently be “drowned out” by genes with a larger
effect size36. As we were particularly interested in the role that RBPs play in B-ALL, and their effect size in cell
lines is unknown, we chose to perform a sub-genomic essentiality screen targeting a pre-defined set of RBPs
known to be highly expressed in B-ALL. Therefore, under the hypothesis that a significant proportion of the
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Figure 4.  USO1 depletion significantly affects gene expression and pathways related to cell survival and
proliferation. (A) Enrichment plots generated by the Metascape gene list enrichment analysis webtool on for
the RNA-seq data from USO1-depleted versus NT control SEM cells. The top and bottom panels show pathways
that are downregulated and upregulated in USO1-depleted SEM cells, respectively. (B) Volcano plot representing
differentially expressed genes (Padj < 0.01 and Log2FC > 1.5) with several examples highlighted from the
pathways enriched in (A). (C, D) RT-qPCR validation of differentially expressed genes identified in (B) (t test;
*P < 0.05; **P < 0.01) (E) Western blot showing mildly reduced expression of p-MTOR (Ser2481) expression in
USO1-depleted cells, compared to NT control, while MTOR remains unchanged. (F) Venn diagrams showing
the number of shared genes between USO1-positively correlated genes in Target-Phase II ALL dataset with
the genes that are significantly upregulated (top) or downregulated (bottom) in USO1-depleted SEM cells. A
hypergeometric test was utilized to compare the overlaps between the datasets using a genome size of 24,278
genes. Total and shared number of genes are indicated.
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Figure 5.  USO1 depletion in transformed bone marrow cells shows reduced proliferation and colony forming
potential. (A) Schematic of an in vitro model system to transform Lin- bone marrow cells from Cas9-egfp
mice using overexpression of MLL-Af4 transgene in. (B) Analysis of overexpression of MLL-Af4 by RT-qPCR
and western blot in retrovirally transduced Lin-Cas9MLL-Af4 cells, Lin-Cas9 cells were used as negative control
and 70Z/3 cells transduced with MLL-Af4 were used as positive control. RT qPCR was performed with an
optimized set of primers, normalized to L32, and represented as fold-change from an internal control for each
experiment. Western Blotting was performed with an antibody to MLL1. Vinculin was used as a high molecular
weight loading control. (C) Upper panel, schematic of murine Uso1 depletion experiments, showing location
of sgRNAs relative to the gene, and RT-qPCR primer location. Bottom panel, western blot analysis of 70Z/3
cells transduced with three different sgRNAs targeting Uso1 (msg1-3) cloned in the MSCV.sgRNA.mCherry.
v1 vector. (D) RT-qPCR analysis of Uso1 depletion in 70Z/3 cells. (E) MTS assay (Absorbance at 490 nm) to
measure proliferation in Uso1-depleted 70Z/3 cells compared to NT control cells. (F) FACS plot showing gating
schema to sort the L
 in-Cas9MLL-Af4 GFP+ mCherry+ population following transduction with the Uso1 msg3
vector. (G) Western blot was used to confirm the reduction in USO1 expression in sorted L
 in-Cas9MLL-Af4 cells.
(H). Colony formation assay using Lin-Cas9MLL-Af4 cells in methylcellulose assay as described in methods with
titration of input cell number (t test, ***P < 0.001; ****P < 0.0001).
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sgRNAs would have a negative effect on cell viability, our design included a substantial number of both positive
and negative control sgRNAs in order to properly model the null effect distribution and compare the effect size of
functional RBPs to that of known essential genes. Secondly, the use of a non-MLL-AF4 control cell line allowed
us to identify those proteins whose expression might be most important in MLL-AF4 leukemia. Supporting the
idea that such specific effects may not be seen in genome scale studies, USO1 dropout was detected in one prior
genome-scale analysis, whereas it was not observed in two other genome scale studies that queried vulnerabilities
in MLL-translocated leukemia17,37,38. Thus, our approach to perform this type of CRISPR/Cas9 screen may help
inform the design of future forward genetic screens.
Our group is interested in understanding RNA binding proteins in B-ALL, and we recently described the
functional role of IGF2BP3 in pathologic expansions of cells within the hematopoietic system and its requirement for survival and growth in B-ALL cell lines15. Here, we focused on USO1, based on its identification in
this screen as well as a prior study in MV-4–11 AML cells that had identified USO1 as a factor required for
AML survival17. A recent study reported a KMT2A(MLL)-USO1 fusion gene in a secondary AML, hinting at
a further connection between MLL-driven leukemia and USO139. More generally, USO1 has been shown to be
of functional importance in c ancer23–25. USO1 was recently reported to have RNA-binding function in studies
utilizing high-throughput biochemical t echniques16,40,41, despite a canonical role in the regulation of vesicular
transport42,43. Adding to these prior descriptions of USO1 function, we validated USO1 as a MLL-AF4-induced
gene, and found that it was functionally required in cell lines and in primary bone marrow for MLL-AF4 dependent phenotypes. This work firmly establishes the significance of this protein in acute leukemia, which was not
previously appreciated.
Recent studies in multiple myeloma have shown that USO1-deficient cells showed have reduced cell proliferation and increased apoptosis via regulation of Erk pathway a ctivity24. Transcriptome analysis of USO1-depleted
SEM cells in our study demonstrated a mixed picture, with the downregulation of certain cancer and cell growthrelated pathways, including mTOR and ERB2, but concurrent downregulation of RNA metabolism and MYC
targets. Curiously, there was also upregulation of the mTORC1 hallmark pathway in USO1-depleted cells (as
opposed to downregulation of mTOR generally), perhaps indicating a specific effect on mTORC2. Nonetheless,
we observed decreased phospho-mTOR, which is consistent with the effect seen on cell growth and cell cycle.
Additionally, our data suggests that USO1 is associated with other molecular functions of gene regulation, such as
RNA homeostasis. Interestingly, the pathways noted to be deregulated show similarity to those deregulated upon
inhibition of the RNA demethylase F
 TO44. It is important to note, however, that we have not characterized its
function as a RBP. It is tempting to speculate that USO1 is a bifunctional protein with roles in vesicular transport
and RNA binding, perhaps in a manner similar to YBX145. YBX1 appears to bind to and sort microRNAs, specifically, miR-223, into exosomes. By regulating this process, YBX1 can impact cellular homeostasis. Hence, further
work to assess the molecular role of USO1 as a putative RBP in MLL-AF4 translocated leukemia is warranted.
Overall, our study successfully queried the functional relevance of a set of genes identified from primary
patient samples using expression profiling. Here, we provide a rubric for how to functionally analyze a prioritized list of genes in leukemogenesis, or in other pathogenetic processes. In addition, we establish a role for the
putative RBP, USO1, in leukemogenesis. Given the broader range of cancer types that show USO1 dysregulation,
our work may have implications beyond those in B-ALL. Furthermore, understanding how non-canonical RBP
may participate in leukemogenesis may open up new avenues in developing novel strategies for the diagnosis,
prognosis, and treatment of B-ALL.

Methods

Cell lines and cell culture. All the cell lines involved in the study were maintained at 37 °C in a humidified incubator at 5% C
 O2. RS4;11 (ATCC CRL-1873), NALM6 (ATCC CRL-3273) were cultured in RPMI 1640
supplemented with 10% FBS. 70Z/3 (ATCC TIB 158) cells were cultured in RPMI 1640 supplemented with 10%
FBS and 0.05 mM 2-mercaptoethanol. SEM cells (DMZ-ACC 546), MV-4–11 (ATCC CRL-9591) were cultured
in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% FBS. Mouse bone marrow derived
Lineage (Lin-) cells were cultured in IMDM media supplemented with 15% FBS, 20 ng/mL mTPO, 20 ng/FLT3
ligand and 50 ng/mL mSCF.
Sub‑genomic CRISPR screen. A sub-genomic CRISPR/Cas9 screen was designed to target 36 RBP genes
and 12 “positive control genes”, and included 28 negative control (or non-targeting) single guide RNAs (sgRNAs). The positive control genes, representing known vulnerabilities in MLL-translocated acute leukemia, were
selected from top 100 genes dysregulated in Genome wide CRISPR screen in MV-4–11 cells17. These genes are
expected to “drop out” in a CRISPR screen of MLL-translocated leukemia, but it is not known whether they are
specific for MLL-translocated leukemia. This design was adapted to provide enough non-targeting controls in
the context of a sub-genomic screen, where a significant proportion of targeting sgRNAs may be expected to
change. Five sgRNAs were designed for each RBP or positive control genes, using sgRNA design tools from
Broad Institute46. pLKO5.sgRNA.EFS.tRFP is a lentiviral vector, which contains EF-1 alpha binding sequence
(EFS) upstream of tRFP, was obtained from Addgene (#57,823)47. The 268 pooled sgRNA were then cloned into
pLKO5.sgRNA.EFS.tRFP lentiviral vector using standard p
 rotocols17. Prior to CRISPR/Cas9 screening, B-ALL
33
cell lines with MLL-AF4 translocation (SEM) and without MLL-AF4 translocation (NALM6)48 were stably
transduced with pLentiCas9-GFP49 lentivirus and sorted on GFP positivity, with subsequent confirmation of
Cas9 expression (Supplementary Fig. 1A). pLKO5.sgRNA.EFS.tRFP lentiviral pool titers were calculated from
SEM and NALM6 cell transduction. For experiments, bulk G
 FP+ SEM and NALM6 cells were infected at < 0.3
6
+
+
MOI and 2 × 10 cells GFP tRFP were sorted by FACS after 48 h of infection (Supplementary Fig. 1B). Genomic
DNA (gDNA) isolated from 106 cells was used for construction of the Reference (REF) library sample, and
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the other 1 06 cells were cultured and expanded. Cells were split every five days and 1 06 cells were reseeded for
culture50 to maintain a sgRNA representation of 3700X. Following 28 days of culture, cells were harvested and
gDNA was isolated for the Depletion (DEP) library sample preparation.

Library preparation, DNA sequencing, and analysis. Sequencing libraries were prepared from both
the Reference (REF) and Depleted (DEP) genomic DNA (gDNA) samples obtained at days 0 and 28 of CRISPR
screen experiment, respectively17,50. Libraries were prepared from 200 ng of input DNA, by using Q5 highfidelity DNA polymerase (#M0492S, NEB) and Illumina adapted primers to amplify the sgRNA target region
from the gDNA, as previously d
 escribed17 (Supplementary Fig. 1C). The purified PCR product was quantified
using Qubit and quality control was done using Bioanalyzer and sequenced on HiSeq 3000 at the Technology
Center for Genomic and Bioinformatics at UCLA. Adapter sequences were removed using in-house scripts.
Candidate reads (those containing a valid primer sequence and with a minimum length of 20 bp after trimming)
were aligned to the sgRNA library using bowtie v0.12.851 with a maximum tolerance of one mismatch. Counts
tables for both individual sgRNAs and gene-level summaries were compiled from non-ambiguous hits for both
the Reference and Depletion libraries in each experiment and for each cell line. Count tables were processed with
DESeq248 to obtain variance-stabilized normalized abundance and rank sgRNAs and genes based on differential
abundance (moderated fold change and adjusted Wald test p value).
Cell line treatment with transcription inhibitors. B-ALL cell lines were plated at 0.5 × 106 cells/
mL density 24 h before treatment, and harvested 48 h after initiating treatment with the chemical inhibitor.
I-BET151, a BRD4 inhibitor was reconstituted in DMSO (10 mM), was diluted in complete media and added to
the cells at a concentration of 0.5 µM, 1.0 µM and 2.0 µM. MI-503, a menin-MLL inhibitor, was used to treat the
cells at 0.12 µM, 0.25 µM and 0.5 µM. EPZ5676, a DOT1L inhibitor, was used to treat cells at a concentration of
0.5 µM of EPZ5676.
Cell proliferation, cell cycle and apoptosis assays. Cell proliferation assay was performed using

standard MTS assay protocol. 5000 cells were plated in 100 µL volume of media in a single well of 96-well tissue
culture plates. Cells were harvested at different time points of day 0, day1, day 3 and day 5. MTS reagent mix
was prepared by adding 100 µL of PMS solution (0.21 mg/mL) to 1 ml of MTS reagent (0.33 mg/mL) and 20 µL
reagent mix was added to each well. The plate was incubated at 37 °C for 2 h and absorbance was taken at 490 nm
in a microplate reader.
Cell cycle analysis was performed using propidium iodide (PI). Cells were harvested and washed in PBS and
fixed in 70% ethanol overnight at − 20 °C. Fixed cells were washed with PBS and centrifuged at 2500 rpm. PI
solution (2 mg/10 mL) was diluted in PBS and added with 0.2 mg/mL of DNase free RNase A. Nearly, 300 µL
of the PI solution was added to each tube and incubated at RT for 2 h. The stained samples were analyzed by
flow cytometer.
Annexin V staining was performed to study the apoptosis in the cells using standard protocol. Briefly, cells
treated with inhibitors/siRNAs were harvested and washed in PBS before resuspending in binding buffer ( 106/
mL). 100 µL of cell suspension was stained with 0.5 µL of Annexin V antibody conjugated to Pacific blue and
incubated at RT for 30 min. After incubation, 300 µL of binding buffer was added to the sample and analyzed
by flow cytometer.

siRNA knockdown of cell lines. siRNA transfection was performed using standard Nucleofection program provided by the manufacturer. SEM cells were Nucleofected using the 4D Nucleofector System (Lonza,
Cologne, Germany). Cells were washed with phosphate-buffered saline and then resuspended in nucleofection solution (SF Cell Line 4D-Nucleofector X Kit, Lonza, Cologne, Germany), at a final concentration of
2 × 106 cells/100 µL reaction. Cells were nucleofected with 30 pmol of control siRNA, USO1 siRNA1, or USO1
siRNA 4, in 100 µL cuvettes using program CV-104. Immediately after nucleofection, 500 µL of pre-warmed,
antibiotic-free media was added to the cuvette and incubated for 10 min at RT. After incubation cells were transferred to a 12 well plate containing 1.5 mL of media. Nucleofected cells were maintained at 37 °C and 5% CO2
prior to harvesting for analysis.
RT‑qPCR assays.

Previous protocols were adapted for RT-qPCR, based on our prior work15. A full list of
RT-qPCR primers is presented in Table S2. For normalization, we utilized RT-qPCR primers for 18S (human)
and L32 (mouse).

Western Blotting.

Western Blotting was performed as previously described15. The blots were developed
and imaged on ECL film or on a Bio-Rad Chemidoc digital imager using Super signal West Pico PLUS chemiluminescent reagent. EPRS (#A303-957A), EIF3E (#A302-984A), USO1 (#A304-513A) antibodies were purchased
from Bethyl laboratories. USO1 (13,509–1-AP) antibody to detect mouse USO1 was purchased from Proteintech. MTOR (#2972 s) and Phospho-MTOR (Ser2481) (#2971) antibodies were procured from Cell Signaling
Technology. Vinculin (Santa Cruz Biotechnology, # sc-73614) and Anti-β-Actin (Sigma Aldrich, #A1978) were
used for loading controls.

Chromatin immunoprecipitation (ChIP). SEM cells were cultured with and without I-BET151 (Sigma
Aldrich,# SML0666) and DMSO for 48 h at 37 °C52. ChIP was performed using EZ-Magna ChIP kit (Millipore,
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# 17–408) with MLL1 antibody (Bethyl laboratories, #A300-374A) and AF4 antibody (Abcam, #ab31812). The
purified DNA was used as input for qPCR and binding was quantitated as previously d
 escribed52.

Immortalization of Lin‑ bone marrow cells. All mice used in this study were obtained from Jackson
Labs and were genotyped according to JAX protocols and maintained in the UCLA Division of Laboratory
Animal Medicine. Bone marrow cells from C57BL6/J Cas9-EGFP mice53 (Jackson Laboratories, # 026,179) were
isolated by flushing the bones from the mice and creating a single cell suspension. Cells were incubated with a
lineage antibody cocktail and depleted for L
 ineage+ cells using MACS technology (Miltenyi Biotech). L
 in- cells
were spin-infected and transduced with MLL-Af4 retroviral p
 reparation33. The MSCV-MLL-flag-Af4 plasmid
was the kind gift via MTA by Dr. Michael Thirman (University of Chicago, Department of Medicine). After four
rounds of transduction, cells were selected in 400 µg/mL G418 supplemented media for 7 days.
MSCV sgRNA vectors. We generated a novel MSCV vector that can overexpress an individual sgRNA in
addition to an mCherry reporter. In brief, the MSCV.mU6.sgRNA-EFs.mCherry.v1 retroviral vector was constructed by replacing a 2.1 kb EGFP-PGK.Puro fragment from the pMGP vector with a 2.7 kb sequence containing mU6.BbsI-stuffer-BbsI-scaffold-spacer-EFs.mCherry via BglII/ClaI digest. The sgRNA scaffold and EF-1α
short (EFs) promoter elements were derived from the pLentiCRISPRv2 vector. The mU6 promoter was designed
from the GenBank sequence NC_000076.6 (nt 79,908,880–79,909,195). A silent mutation was incorporated
into the mCherry reporter element to remove an internal BbsI restriction site. The 1.2 kb stuffer sequence was
derived from portions of the 1.8 kb firefly luciferase gene. The sgRNA sequences targeting mouse were designed
as above and directionally cloned between the mU6 promoter and sgRNA scaffold sequence via BbsI. Detailed
methods and vector maps are available upon request.
Colony forming unit assay. A colony forming unit assay was performed to study the effect of USO1depletion on the colony forming potential of Lin-Cas9MLL-Af4 cells. The assay was performed using the Methocult colony forming media (STEMCELL Technologies, #M3434)54. Briefly, approximately 5,000 L
 in-Cas9MLL-Af4
USO1 depleted cells were mixed in 3.2 ml of overnight thawed Methocult media and plated in two 35 mm
dishes along with the NT controls and cultured for 12 days. After 12 days of culture, individual 35 mm dishes
were counted for both total number and morphologic subtypes of colonies formed by USO1 depletion and NT
control cells.
RNA‑Seq library preparation and analysis. Libraries for RNA-Seq were prepared with Nugen Univer-

sal plus mRNA-Seq Kit to generate strand-specific RNA-seq libraries. Sequencing was performed on Illumina
HiSeq 3000 SR 1 × 50 bp run. Data quality check was done on Illumina SAV. Demultiplexing was performed with
Illumina Bcl2fastq2 v 2.19.1.403 program. The STAR ultrafast universal RNA-seq aligner v2.7.0d55 was used to
align the reads to a genome index that included both the genome sequence (GRC38 human primary assembly)
and the exon/intron structure of known human gene models (Gencode v29 genome annotation). Alignment
files were used to generate strand-specific, gene-level count summaries with STAR’s built-in gene counter. Independent filtering was applied as before56,57: genes with less than 6 total counts across all samples, count outliers,
or low mappability (< 50 bp) were filtered out for downstream analyses. Expression estimates were computed in
units of fragments per kilobase of mappable length and million counts (FPKMs). Differential expression analyses between USO1 depletion and non-targeted controls was performed with D
 ESeq227 and genes were ranked
based on moderated fold change and adjusted Wald test p value. Functional enrichment for selected genes was
performed with Metascape36.

Approvals and Compliance. This study was carried out in compliance with the ARRIVE guidelines. All
animal experiments were carried out in accordance with relevant guidelines governing the use of animals in
research. In addition, all experiments involving animals were approved by the University of California, Los
Angeles, Chancellor’s Animal Research Committee (ARC), which was established for compliance with Public
Health Service (PHS) guidelines on animal research.

Data availability

All sequencing data have been deposited in the Sequence Read Archive (PRJNA658354). All research materials
will be made available in accordance with UCLA policy.
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